Making commonly used antimicrobial products like athlete’s foot, vaginal thrush treatments and cold sore creams available only with a prescription in Europe could cost the region close to €10bn ($10.6bn) a year in additional health expenses, according to IQVIA.
Reverse-Switching OTC Antimicrobials Could Cost Europe An Additional €10bn Per Year
Over five years, the cost of the European Commission's proposal could exceed a total €50bn, finds a study by IQVIA commissioned by the AESGP.
